All Headlines >>
The company says the product is highly effective against common bacteria including Staphylococci, Clostridia, Corynebacteria and Streptococci, and gram-negative bacteria including Bacteroides spp, Pasteurellae, and Proteus spp.
Clavubactin is available in a range of dose strengths to treat all sizes of patient. It is presented as a doubly divisible tablet for accurate and flexible dosing and to help avoid the development of antibiotic resistance associated with under dosing. The tablets come in blister packs of 10, designed to help reduce unnecessary exposure when dispensing in practice.
Dechra Brand Manager Carol Morgan said: "The introduction of Clavubactin to our antibiotic portfolio will give veterinary professionals even more choice of effective and targeted treatments in their day-to-day practice."
PS: Whilst you're here, take a moment to see our latest job opportunities for vet nurses.
Would anybody from Dechra like to reveal what is happening re Phenaleptil? Is it discontinued or is it coming back? Conflicting information depending on who you talk to